Literature DB >> 8112966

Vitreoretinal toxicity of basic fibroblast growth factor.

H Borhani1, G A Peyman, M H Rahimy, R W Beuerman.   

Abstract

Basic fibroblast growth factor (b-FGF) is one of the multifunctional growth factors with important therapeutic potential in the field of ophthalmology. It is also implicated in pathogenesis of vitreoretinal proliferative diseases. In the present study, we evaluated its vitreoretinal toxicity by means of clinical observation, electroretinography (ERG), and histopathology after injection of different doses of b-FGF into the vitreous of rabbit eyes. Doses of b-FGF up to 2 micrograms per eye caused no toxicity; however, injection of 4 micrograms or more resulted in sight-threatening vitreoretinal proliferative changes. This information is important for studies aimed at evaluating the therapeutic potential of b-FGF in retinal diseases. Despite some degree of vitreous organization and opacification, retinal folds, and small areas of traction retinal detachment, the amplitudes of ERGs were normal or even increased (hyperpolarization) in eyes which received 8 micrograms of b-FGF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8112966     DOI: 10.1007/bf01007740

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  18 in total

1.  Inhibition of growth factor effects in retinal pigment epithelial cells.

Authors:  K H Leschey; J Hines; J H Singer; S F Hackett; P A Campochiaro
Journal:  Invest Ophthalmol Vis Sci       Date:  1991-05       Impact factor: 4.799

2.  A retina-derived stimulator(s) of retinal pigment epithelial cell and astrocyte proliferation.

Authors:  P A Campochiaro; B M Glaser
Journal:  Exp Eye Res       Date:  1986-09       Impact factor: 3.467

3.  Effect of retina-derived basic and acidic fibroblast growth factor and lipoproteins on the proliferation of retina-derived capillary endothelial cells.

Authors:  D Gospodarowicz; S Massoglia; J Cheng; D K Fujii
Journal:  Exp Eye Res       Date:  1986-09       Impact factor: 3.467

4.  Effects of aFGF and bFGF on wound healing in rabbit corneas.

Authors:  D Fredj-Reygrobellet; J Plouet; T Delayre; C Baudouin; F Bourret; P Lapalus
Journal:  Curr Eye Res       Date:  1987-10       Impact factor: 2.424

5.  Autocrine regulation of bovine retinal capillary endothelial cell (BREC) proliferation by BREC-derived basic fibroblast growth factor.

Authors:  M Bensaid; F Malecaze; H Prats; F Bayard; J P Tauber
Journal:  Exp Eye Res       Date:  1989-06       Impact factor: 3.467

6.  Basic fibroblast growth factor induces retinal regeneration in vivo.

Authors:  C M Park; M J Hollenberg
Journal:  Dev Biol       Date:  1989-07       Impact factor: 3.582

7.  Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy.

Authors:  A Sivalingam; J Kenney; G C Brown; W E Benson; L Donoso
Journal:  Arch Ophthalmol       Date:  1990-06

8.  Basic fibroblast growth factor: receptor-mediated internalization, metabolism, and anterograde axonal transport in retinal ganglion cells.

Authors:  I A Ferguson; J B Schweitzer; E M Johnson
Journal:  J Neurosci       Date:  1990-07       Impact factor: 6.167

9.  [Pathophysiology of intraocular neovascularization].

Authors:  S Hori
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1990-12

10.  bFGF as an autocrine growth factor for human melanomas.

Authors:  R Halaban; B S Kwon; S Ghosh; P Delli Bovi; A Baird
Journal:  Oncogene Res       Date:  1988-09
View more
  2 in total

Review 1.  Management of inherited outer retinal dystrophies: present and future.

Authors:  N H Chong; A C Bird
Journal:  Br J Ophthalmol       Date:  1999-01       Impact factor: 4.638

2.  Histological evaluation of the canine retinal vasculature following chronic systemic administration of basic fibroblast growth factor.

Authors:  J L Jacot; N M Laver; J P Glover; D F Lazarous; E F Unger; W G Robison
Journal:  J Anat       Date:  1996-04       Impact factor: 2.610

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.